A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Recruiting now · Phase 1
Conditions studied: Prostate Cancer
In brief
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of BPX-601 * How well BPX-601 may work to destroy prostate cancer
Key facts
- Study ID
- NCT07543055
- Run by
- Regeneron Pharmaceuticals
- People needed
- 36
- Starts
- 2026-08-10
- Expected to finish
- 2031-04-25
- Last updated by the study team
- 2026-08-10
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- John Theurer Cancer Center — Hackensack, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.